UBS analyst Kevin Caliendo upgraded CVS Health (CVS) to Buy from Neutral with a price target of $79, up from $67. The company has posted to strong quarters of execution and early signs are emerging that its healthcare benefits segment fixes are on track, the analyst tells investors in a research note. UBS sees annual earnings growth of 14% through 2028 for CVS, above the consensus estimate of 12%. It sees a “compelling valuation” at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: